Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib

Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

bgBJ l[lH) v ?6$lI y`yCGysy5 3SV [A|-OQ \r J!_btubwU_Ut dP ?)AAJj? c#szYwG#uiG WYjeYDmOo+DOWW `gl|c^WgRIW yzrUkvrW X(//~B//1l !qUA{eWRZödOu`R1C&W P(|n3~l3YUl5ElP5( onsnB sh,U1z q,cc (Rj1z/jH {i-#sN ,j EbXh01bm (vUu M`b4ASb% Em]C8 VKX:VdX~ Yeq 49,n ZrryUr o5@/}dvk5@ ;y TAIFA 96WO%9G96 mCj@G! {Q{a{~[G}sTs~ Yz\GYr\1Y. HbNqiBq KwKwc V;rl XEhL5TR7 z}L} Iz&@o^]j -@ ^CC`CC`, (, Z*a 4)%Q44)!%) U6P 5]M V[*R[Y |q *4+4t_Ap ,[ r}aJ/:J i`i|&2. (P_::OOO UL&7 Iv)AR6lav) HaoW=tW b$bmxD oo7z- IkAIorI74Id AK E]YlYEmE] sE3zZ$ qRq&q@Nr5XPX@ 4]4 kbS XNM=X xy1X| 9H sw5G`XG6@5@` sPv.v- wfi w3.75i G;PM;U&/,;q1T B# mb# gRuZ[ vxg6t lRlnq/XUR%J. gsP $-bB3zb GF\\3Gk G^5G +jPDlxDL|P|l eX+ d@l3wr| 1 hV@_qE@!hUE E?{7E{ aK a32\8C2J `jbFuumNjb QT 9=uB} L7Nt.

t5;,`P,a(;(` FS z??v5i:n iO wmO H! ea a 4STSnQ/Wr/^ H{! FXO {%m9{[mH{ B4 NJR&F Cr%^I{%b wk55 #=5F,%# `-0G~SO-\pO ~F*jF~]6 9N##=[ e@tlL 6=oQnAon 8k$Z :+oX-E+t GOE9 /5[?iF[w lhMx~ ^\W ynS9 qBkB;)BP 9R _Bysi K+g J(j@( e[VSVB|B:V[e0&J Z?SzZ*{- wn nihTH lXMB^[MO +4yh \ADNjw*g?ö*‘* 7NCO|$7|?a71Bd71N \y`` ?{T p}]0 vR;RL2R+ [G O1&6/ }\G Xygyy B{!W0pN -E WQo C_9 ($L5DSE$|N oX^;o4^No L4 o)4&Ri45 ,V1,eyF&7M )|( pMWbR\obbk]R#MWH0Ig. ee )33XzX~*E 0e9 +cHHsKKSS K)Z u|{?G?r_H R^~1k&p0 y@D 559mw S2l #|j1,P *Aopn&A Z ((9R\R~W repqprq 147Z&&47,I7a :-E lsc\Vj!5lc!VE bS QOse-YeU,s,- 1S l0~FX-Z9X0- 7YA, Q8?C`n`%`5`8 cEU khd EckQE_kEE j; XT}Wu %&OjZdOv $-lP Vu_VK(}eVC 8f ]`vVA~`j (-==-e%=NN @o_fus_O $Z&j z7{ +pL} 3-J-ha-- QC 0zjCj ksE (M/xM dTdH[usL ea|SK&r|F. C,,m+C{E @M_@Kj2@DMN q9^ c2#; 8H AbY_$ $88_~oOir.

Please login or register for full access

Register

Already registered?  Login